MAGEA3 and cancer: The modification of substrate ubiquitination results in a cascade of signaling that leads to pleotropic effects such as altered vesicular trafficking (MAGEL2/TRIM27) [48], metabolic reprogramming and, therefore, the proliferative capacity of cells (MAGEA3/6/TRIM28) [7], and 3′ UTR shortening through alternative polyadenylation in cancer cells (MAGEA11/HUWE1) [8].